Dactil

Quick links to important sections

Dactil

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dactil

Quick Facts: Dactil (Piperidolate Hydrochloride)

Property Description
Active ingredient Piperidolate hydrochloride
Form Oral tablet (film-coated)
Pharmacological class Anticholinergic agent / Antimuscarinic agent
General purpose Relief of smooth muscle spasms and cramping
Origin Synthetic compound (piperidine derivative)

Dactil: Identity, Origin, and Pharmaceutical Form

Dactil is a pharmaceutical preparation whose active component is the synthetic compound Piperidolate hydrochloride, a substance derived from the piperidine chemical structure. This single-ingredient medication is typically manufactured as a stable, film-coated oral tablet for systemic action. The use of the hydrochloride salt form ensures the substance's optimal stability and efficient absorption following the oral route of administration. This formulation means the drug is chemically prepared to be efficiently absorbed and distributed in the body to target involuntary muscles deep within the digestive system, a feature clinically recognized for managing internal visceral distress.

What Type of Medicine is Dactil?

Dactil is categorized pharmacologically as an antimuscarinic agent, which is a specific subtype of anticholinergic agent. This classification means its action directly involves modulating the signaling of the neurotransmitter acetylcholine by acting as a receptor antagonist. This mechanism affirms Dactil's intended function: to interrupt the chemical signals that trigger excessive muscle contraction. This mechanism grants the drug a differentiating antispasmodic effect, making it a primary choice for conditions characterized by uncontrolled muscle activity.

General Purpose and Benefit of Dactil

The general purpose of Dactil is to alleviate the distress and pain associated with spasmodic disorders and hypermotility of the gastrointestinal system. By blocking the nerve signals responsible for involuntary muscle tightening, the medication facilitates the essential relaxation of the smooth muscles within the digestive tract. This focused action reduces the frequency and severity of cramping, thereby restoring a more coordinated and comfortable rhythm to the gut. It is typically employed when smooth muscle spasms, rather than inflammatory processes, are the root cause of discomfort.

Regulatory References

  1. PIPERIDOLATE HYDROCHLORIDE substance record

What side effects are possible with Dactil?

Possible Side Effects and Safety Information

The safety profile of Dactil (Piperidolate hydrochloride), an anticholinergic agent, is primarily characterized by the side effects expected of this pharmacological class and specific documented safety constraints.

Adverse reactions are officially categorized by the system or organ affected. The frequency classification for all listed reactions is generally reported as incidence unknown, reflecting that official incidence surveys were not performed during certain regulatory periods.


Documented Adverse Reactions by System-Organ Class

The reported side effects affect several physiological systems, including Ophthalmic, Gastrointestinal, Urologic, Psychoneurologic, and Cardiovascular systems. Commonly observed effects, categorized by their systemic domain, may include:

  • Gastrointestinal: Thirst, constipation, nausea/vomiting, and anorexia.
  • Ophthalmic: Mydriasis (dilation of the pupil).
  • Urologic: Dysuria (painful or difficult urination).
  • Psychoneurologic: Dizziness.

Significant Safety Considerations

A potential significant adverse reaction documented in official labeling is Hepatic dysfunction and jaundice. This condition is typically characterized by marked increases in liver enzymes, including AST (GOT), ALT (GPT), gamma-GTP, and total bilirubin. When such adverse reactions or any other abnormalities like mydriasis or dizziness are observed, regulatory documents direct that administration should be discontinued.

Population and Activity Safety Notes

The label includes specific safety considerations for Use in the Elderly, as this population may be more susceptible to the medicine's effects. Furthermore, due to the potential for effects such as mydriasis and dizziness, patients are advised in official regulatory texts to use caution regarding engagement in potentially hazardous activities requiring alertness, such as driving or operating machinery.

Overdose and Emergency Response

Overdose of Piperidolate hydrochloride is formally documented by regulatory authorities, with manifestations consistent with severe anticholinergic toxicity. Official documentation states that overdose may present with signs such as psychomotor agitation and potentially severe neurological events, including seizures or convulsions. The primary life-threatening outcome cited in regulatory information is the exacerbation of antimuscarinic effects.

Regulatory guidance mandates that individuals must seek medical attention immediately upon any suspicion of overdosage. Emergency response, as described in regulatory labels, is symptomatic and supportive, as no specific antidote is known for Piperidolate overdose. Documented procedural steps for managing overexposure include gastric lavage and the use of activated charcoal to reduce systemic absorption. For controlling acute neurological manifestations, the administration of Diazepam is listed. A critical management constraint noted in official labeling is the requirement to avoid phenothiazines, as these agents carry a specific risk of exacerbating the already dangerous antimuscarinic effects. All supportive measures are required as part of ongoing professional care.

Therapeutic Uses of Dactil

Uses and Benefits in Pregnancy Support

Dactil (often formulated as Dactil-OB, combining piperidolato, hesperidin, and ascorbic acid) is conventionally used as an auxiliary treatment in specific at-risk pregnancies. Its primary therapeutic domain is offering support during gestation where there is a clinical need to address premature uterine contractions.

The medication may be clinically utilized as an adjunctive measure to assist in managing threatened preterm birth, which is defined as the onset of labor before the thirty-seventh week of gestation. Through its intended actions, Dactil supports the overall management plan designed to promote favorable continuation of the pregnancy until the term date or until the clinician determines the appropriate time for delivery.

This specific medical context requires direct clinical oversight and is part of a larger, physician-directed strategy for high-risk pregnancies.


Quick Facts: Therapeutic Applications

  • Addresses: Threatened preterm birth (onset of labor before 37 weeks).
  • Purpose: To offer support in controlling premature uterine activity.
  • Function: May promote the continued maintenance of the pregnancy in at-risk cases.
  • Role: Used as an adjunctive measure within a comprehensive clinical management strategy.

Eligibility and Restrictions for Use

Dactil (Piperidolate Hydrochloride) is an antispasmodic medication primarily intended for use in adults. Official regulatory documents strictly define populations who must not use the medicine and those who require careful administration.

Contraindications: Who Must Not Use Dactil

Based on official labeling, the medicine is contraindicated and must not be used by patients with:

  • Glaucoma (due to risk of increased intraocular pressure).
  • Serious Cardiac Disease.
  • Paralytic Ileus (intestinal paralysis).
  • Dysuria due to Prostatic Hyperplasia (difficulty urinating caused by an enlarged prostate).
  • A history of Hypersensitivity to any component of the product.

Restricted or Conditional Use

Careful administration and heightened clinical monitoring are required for patients with prostatic hyperplasia (non-dysuric), congestive heart failure, arrhythmia, ulcerative colitis (risk of toxic megacolon), and hyperthyroidism.

Pregnancy and Age Eligibility:

Category Eligibility Status (Official Labeling)
Pregnancy Conditional use documented for threatened premature birth (combined Dactil-OB formulation).
Lactation Use requires careful consultation with a healthcare professional.
Pediatrics Use is primarily established for adults; no specific minimum age is listed as a formal contraindication.

Eligibility criteria are governed by the drug's anticholinergic properties and its potential to aggravate these specific pre-existing conditions.

What should I know about interactions with other medicines?

The official regulatory documentation for Dactil (Piperidolate Hydrochloride) defines its interaction profile predominantly through pharmacodynamic interactions that lead to the enhancement of the drug's primary effect. The interaction scope focuses on specific classes of medicines that possess similar anticholinergic properties, potentially resulting in additive effects when co-administered. The documentation does not specify any interaction-related timing separation requirements or pharmacokinetic changes involving metabolic enzymes or transporters, as these are not officially noted in the regulatory labels.

Interaction Type Interacting Product Categories Official Description
Pharmacodynamic Monoamine oxidase inhibitors (MAOIs) May result in enhancement of the product's effect.
Pharmacodynamic Tricyclic antidepressants (TCAs) May result in enhancement of the product's effect.
Pharmacodynamic Phenothiazine preparations Documented additive pharmacodynamic effect.
Pharmacodynamic Antihistamines Documented additive pharmacodynamic effect.

The regulatory constraints emphasize that co-administration with these medicinal categories may increase the overall effect of Dactil, leading to reactions associated with its pharmacological action. The specific interacting medicines noted in regulatory guidance include examples such as Imipramine, Chlorpromazine, and Diphenhydramine. This classification of interaction risk is formally considered clinically significant. Furthermore, there are no official statements within the regulatory documents specifying mandatory restrictions for co-administration with food, alcohol, or herbal products. The profile is strictly limited to the documented drug-to-drug interactions.

Mechanism of Action

Dactil's activity is confined to the peripheral nervous system, engaging a specific mechanism to modulate the activity of peripheral physiological processes in the digestive tract.

The drug, Piperidolate hydrochloride, acts as a competitive antagonist primarily by blocking the muscarinic acetylcholine receptors ( mAChRs) located on smooth muscle cells and glands of the gastrointestinal ( GI) tract. This mechanism engages the cholinergic signaling pathway, interrupting the nerve impulse that normally stimulates these structures.

By interrupting the signaling cascade at the receptor level, Dactil prevents the necessary molecular steps ( Ca^2+ flux) required for muscle contraction. This results in the relaxation of GI smooth muscle. Simultaneously, the receptor blockade on glandular cells reduces nerve-driven GI fluid and acid output, resulting in inhibited secretion. These targeted pathway adjustments modulate the activity levels within the GI system.

The mechanism's scope is physiologically confined to processes driven by cholinergic overstimulation. It engages mechanisms that modulate activity in neural processes, but the mechanism demonstrates a reduced response to physiological signals resulting from non-cholinergic factors, such as local inflammatory mediators like prostaglandins.

Dosage and Administration Information

How Dactil is Used

Dactil, containing the active ingredient Piperidolate hydrochloride, is administered exclusively via the oral route as a 50 mg film-coated tablet formulation. The drug is intended for systemic use, with an administration pattern designed to ensure consistent use.


Standard Dosing and Frequency

The established usage pattern for adults is based on a total daily intake of 150 mg to 200 mg of Piperidolate hydrochloride. This total daily dosage is structured to be taken in three or four divided doses throughout the day. This dosage may be subject to adjustment by the clinician, depending on the patient's symptoms and age.


Procedural Administration Guidelines

Administration Rule Instruction Detail
Route of Administration Ingestion of the oral tablet.
Missed Dose Handling If a dose is missed, it should be taken as soon as remembered. However, if the time for the next scheduled dose is imminent, the missed dose is to be skipped to maintain the proper dosing interval.
Physical Handling For tablets dispensed in a press-through package (PTP), the tablet must be removed from the PTP sheet before being swallowed.
Use in Older Adults The dosage may require reduction and should be used under careful supervision due to potentially reduced physiological functions in the elderly population.

The administration protocol involves a divided daily frequency and provides explicit procedural handling for the physical medication form, such as the requirement to remove the tablet from its packaging prior to ingestion. This protocol establishes the standardized approach to the drug's administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dactil

Evidence for Use in Gastrointestinal Spasmodic Disorders

Piperidolate hydrochloride (Dactil) has been examined in research contexts involving conditions characterized by fluctuating or episodic smooth muscle activity, such as Irritable Bowel Syndrome (IBS). Studies monitored patient-reported outcomes describing perceived discomfort and other outcomes related to systemic imbalance, including the frequency and intensity of cramping. The evidence base is often derived from the broader anticholinergic pharmacological class of medicines. Research describes measurements of patient-reported outcomes, such as changes in abdominal discomfort and cramping, observed over defined time intervals. Evidence quality varies, and large-scale, dedicated research for Piperidolate as a single ingredient is less common in recent comprehensive reviews.


Evidence for Use in Threatened Preterm Birth

Dactil was studied for use in pregnant women experiencing signs of threatened preterm labor, where it is observed as a component in a combination product (Dactil-OB). This research examined the drug as an adjunctive measure, used alongside other care protocols. The studies monitored outcomes related to the duration of gestation, focusing on measurements of a temporary delay in time to delivery and the overall pattern of pregnancy continuation. Evidence derived from these settings often involves older trials and observational studies, making the certainty remain low compared to modern randomized trials.


Long-Term Follow-up and What Research Gaps Remain

The available evidence primarily focuses on research exploring short-term symptom changes or acute management. For chronic functional conditions, long-term effects are not fully established, meaning data for outcomes related to sustained changes in symptoms is limited. Follow-up durations were often short, and data remains insufficient to characterize the durability of observed patterns.

A key gap is that the evidence base for Piperidolate is often associated with research on the anticholinergic drug class rather than large, dedicated trials for the single ingredient. In the obstetric context, studies observed the combination product, making the specific clinical impact of Piperidolate alone uncertain. Furthermore, comparative evidence is lacking against other medicines in the antispasmodic class.

Frequently Asked Questions (FAQ)

Common questions about Dactil (FAQ)


Q: Does Dactil cure IBS or other spasmodic disorders?

Official regulatory documents indicate that Dactil is used to improve convulsive pain and various symptoms related to spasmodic disorders. The documented use in the product information is to alleviate symptoms, and it is not described as a cure for chronic conditions like Irritable Bowel Syndrome (IBS).


Q: What is the appearance of the Dactil tablet (color, shape, markings)?

According to the official product information, the Dactil tablet is white and film-coated. It is described as being round, with specific measurements for its size. These tablets typically feature an identification code or imprint on the surface for recognition.


Q: Is Dactil safe to crush or chew?

Dactil is manufactured as a film-coated oral tablet. Official administration instructions emphasize that the medicine must be removed from its packaging before being swallowed. Regulatory documents do not provide explicit instructions for crushing, cutting, or chewing the tablet. The administration guidelines only direct the swallowing of the tablet after removing it from the package.


Q: What is the maximum daily dose of Dactil?

The established usual adult daily dosage range is specified in the official product information. This intake is structured to be taken in multiple divided doses across the day.


Q: Is Dactil safe for a person with kidney or liver problems?

Hepatic dysfunction and jaundice (liver issues) are documented as potential significant adverse reactions. If these or other abnormalities are observed, official regulatory documents state that administration should be discontinued under medical supervision. Conversely, the product label does not contain specific precautions or dose adjustments related to pre-existing kidney impairment (renal problems).

How should Dactil be stored and disposed of?

The storage and disposal of Dactil (Piperidolate Hydrochloride) tablets must follow the specific conditions required by regulatory guidelines to ensure stability and safety.

Storage Requirements

Scope Element Official Regulatory Requirement
Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection: Store away from direct sunlight, excessive heat, and moisture.
Container: Keep the medicine in the original container and maintain it tightly closed.

Disposal and Safety Rules

Scope Element Official Regulatory Requirement
Child Safety: Keep this medication out of the sight and reach of children.
Disposal: Dispose of unused or expired Dactil through authorized drug take-back programs.
Environmental Rule: The product must not be flushed down the toilet or poured into the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dactil found in:

A-Z Index: